IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Sanofi Beats Estimates Ahead of CEO Transition

Sanofi reported strong first quarter results today driven by high demand for its drug Dupixent. Incoming CEO Belen Garijo will soon take charge to lead growth.

Xurve View
Insights:

SANOFI reported first-quarter earnings on Thursday that exceeded market expectations, driven by robust demand for its flagship asthma and eczema treatment, Dupixent. The results provide a stable foundation for incoming CEO Belén Garijo, a former executive at the firm who previously led Germany based MERCK KGAA. Garijo is scheduled to take the helm by the end of the month following the abrupt departure of former CEO Paul Hudson in February.

The corporate logo of the French pharmaceutical company Sanofi displayed at a location in Paris, France, as photographed on January 9, 2026. REUTERS/Gonzalo Fuentes/File Photo
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.